It is a successful American business with the largest market size and the dream of any businessman. In the United States, law firms, consulting, brokers, lobbyists, etc. have been trained and become part of the literary world, so their role can be an important variable. As a result of recommendations from the U.S. Embassy in Korea and discussions with the CEO in person in the U.S., we had competent experts, and we signed a contract with the expectation of systematic and efficient consulting.

The first project is consulting to introduce a capable and large-scale American partner who will sell FDA 510K certified EZ Regular in the United States.

From 2009 to 2017, it was supplied by Company P, located in St. Louis, Missouri, in the central east of the United States. At the time when tariffs were not an issue, I understand that EZ Regular, which was acknowledged by Company P employees, was replaced with a product from another company due to price competitiveness rather than quality and technological competitiveness. We hope that the new government's tariff policy will provide us with hope. The American partner that Company C plans to introduce is expected to be major in scale.

If the first project was successful and EZ Regular achieved successful results in the United States, we decided to proceed with the Anyfusion project as a second project.  The second project required time, money, and capabilities, so the role of Company C was judged to be important, so a contract was signed. We provide consulting on FDA 510K certification, insurance registration of treatment materials on CMS and ICD, corporate establishment, manufacturing, investment, listing, etc. It is expected that the largest cost will be invested in the work for registration of treatment materials on CMS and ICD, so introducing a US partner that can cover this will be the most important task for the company. We look forward to introducing partners who have considered Anyfusion’s entry into the U.S. market.

Thank you.